From: Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part one
 | CAN 150 mg q4w N = 22 | PBO N = 24 | p-value |
Proportion of responders at Wk 16 (E2), n(%) | 10 (45.5) | 2 (8.3) | 0.005* |
Proportion of patients with no new flare at Wk 40 (E3), n(%) | CAN 150 mg q8w N = 4 | PBO N = 5 | p-value |
3 (75.0) | 2 (40.0) | 0.3571 | |
Safety | |||
 | PBO (N = 24) | Any CAN*, E2 (N = 43) | Any CAN*, E2 + E3 (N = 61) |
Exposure to CAN, pyr | 2.0 | 12.1 | 39.2 |
Number of AEs (AE rate/100 pyr) | 34 (1698.8) | 112 (925.7) | 265 (676.2) |
Number of SAEs (SAE rate/100 pyr) | 1 (50.0) | 3 (24.8) | 5 (12.8) |